The emission of electromagnetic radiation as a result of a chemical reaction that creates light is known as chemiluminescence (CL). CLIA stands for chemiluminescence immunoassay, which combines chemiluminescence with immunochemical reactions. CLIA uses chemical probes that can emit light as a result of a chemical reaction to label the antibody.
Because of its high sensitivity, strong specificity, inexpensive equipment, and wide linear range, CLIA is employed in a variety of sectors, including life science, clinical diagnostics, environmental monitoring, food safety, and pharmaceutical analysis.
Impact of the Coronavirus (COVID-19) Pandemic on the Global Chemiluminescence Immunoassay Market
On December 31, 2019, a Coronavirus (COVID-19) epidemic was first detected in Wuhan, China. COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020.
COVID-19's Effect on Chemiluminescence Immunoassay Demand and Supply
The COVID-19 outbreak and subsequent lockdown in several nations throughout the world have had a financial impact on enterprises in all sectors, including the private healthcare sector. The COVID-19 pandemic has had a significant influence on the healthcare industry's whole supply chain, owing to stringent lockdown in certain places.
Over the projection period, the market is expected to develop due to an increase in the number of disorders needing chemiluminescent immunoassays, such as HIV (human immunodeficiency virus).
The global chemiluminescence immunoassay market is predicted to develop in response to the rising prevalence of human immunodeficiency virus illness (HIV). According to the Centers for Disease Control and Prevention (CDC), 36,801 persons were diagnosed with HIV in the United States and dependent regions in 2019. At the end of 2019, an estimated 1,189,700 people in the United States had HIV, with 15,815 HIV-related fatalities reported.
Competitive Landscape of the Global Chemiluminescence Immunoassay Market
DiaSorin S.p.A., Abbott Laboratories, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers, Beckman Coulter Inc., F. Hoffmann-La Roche AG, Inova Diagnostics, Inc., Maccura Biotechnology Co., Ltd., Tosoh Corporation, and Ortho Clinical Diagnostic are among the major players in the global chemiluminescence immunoassay market.
Impact of the Coronavirus (COVID-19) Pandemic on the Global Chemiluminescence Immunoassay Market
On December 31, 2019, a Coronavirus (COVID-19) epidemic was first detected in Wuhan, China. COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020.
COVID-19's Effect on Chemiluminescence Immunoassay Demand and Supply
The COVID-19 outbreak and subsequent lockdown in several nations throughout the world have had a financial impact on enterprises in all sectors, including the private healthcare sector. The COVID-19 pandemic has had a significant influence on the healthcare industry's whole supply chain, owing to stringent lockdown in certain places.
Over the projection period, the market is expected to develop due to an increase in the number of disorders needing chemiluminescent immunoassays, such as HIV (human immunodeficiency virus).
The global chemiluminescence immunoassay market is predicted to develop in response to the rising prevalence of human immunodeficiency virus illness (HIV). According to the Centers for Disease Control and Prevention (CDC), 36,801 persons were diagnosed with HIV in the United States and dependent regions in 2019. At the end of 2019, an estimated 1,189,700 people in the United States had HIV, with 15,815 HIV-related fatalities reported.
Competitive Landscape of the Global Chemiluminescence Immunoassay Market
DiaSorin S.p.A., Abbott Laboratories, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers, Beckman Coulter Inc., F. Hoffmann-La Roche AG, Inova Diagnostics, Inc., Maccura Biotechnology Co., Ltd., Tosoh Corporation, and Ortho Clinical Diagnostic are among the major players in the global chemiluminescence immunoassay market.
0 Comments